The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Amyloid-β(1–42), Total Tau, and Phosphorylated Tau as Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease
Open accessAbstract
Background: To improve ante mortem diagnostic accuracy of Alzheimer disease (AD), measurement of the biomarkers amyloid-β(1–42) (Aβ42), total tau (Tau), and tau phosphorylated at threonine181 (pTau) in cerebrospinal fluid (CSF) has been proposed. We have used these markers and evaluated their performance. Methods: From January 2001 to January 2007, we assessed Aβ42, Tau, and pTau by commercial ELISAs in CSF from 248 consecutive AD patients and 131 patients with subjective memory complaints attending our outpatient memory clinic. Diagnoses were made blind to the results of the biomarker assays. We assessed sensitivity and specificity and analyzed trends over time. Results: Interassay CVs from analysis of pools of surplus CSF specimens were mean 11.3% (SD 4.9%) for Aβ42; 9.3% (1.5%) for Tau, and 9.4% (2.5%) for pTau, respectively (n = 7–18). To achieve 85% sensitivity, cutoff values were 550 (95% CI 531–570) ng/L for Aβ42; 375 (325–405) ng/L for Tau, and 52 (48–56) ng/L for pTau. Corresponding specificities were 83% (95% CI 76%–89%) for Aβ42, 78% (70%–85%) for Tau, and 68% (60%–77%) for pTau. Logistic regression to investigate the simultaneous impact of the 3 CSF biomarkers on the diagnosis yielded a sensitivity of 93.5% and specificity of 82.7%, at a discrimination line of Aβ42 = 373 + 0.82 × Tau. The area under the ROC curves of Tau and pTau showed significant fluctuation over time. Conclusions: CSF biomarkers Aβ42 and Tau can be used as a diagnostic aid in AD. pTau did not have additional value over these 2 markers. Cutoff values, sensitivities, specificities, and discrimination lines depend on the patient groups studied and laboratory experience.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Hanley, J. A., & McNeil, B. J. (1983) · Radiology · doi:10.1148/radiology.148.3.6878708 · Cited by 7,016
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Doody, R. S., Stevens, J. C., Beck, C., Dubinsky, R. M., Kaye, J. A., Gwyther, L., Mohs, R. C., Thal, L. J., Whitehouse, P. J., DeKosky, S. T., et al. (2001) · Neurology · doi:10.1212/wnl.56.9.1154 · Cited by 1,720
Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700
Alzheimer’s Disease Neuroimaging Initiative
Mueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C., Jagust, W., Trojanowski, J. Q., Toga, A. W., & Beckett, L. (2007) · Advances in Behavioral Biology · doi:10.1007/978-0-387-72076-0_18 · Cited by 1,468
Knopman, D. S., DeKosky, S. T., Cummings, J. L., Chui, H., Corey–Bloom, J., Relkin, N., Small, G. W., Miller, B., & Stevens, J. C. (2001) · Neurology · doi:10.1212/wnl.56.9.1143 · Cited by 1,410
CSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291
CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
Mattsson, N. (2009) · JAMA · doi:10.1001/jama.2009.1064 · Cited by 1,176
Tapiola, T., Alafuzoff, I., Herukka, S.-K., Parkkinen, L., Hartikainen, P., Soininen, H., & Pirttilä, T. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.596 · Cited by 896
Improved discrimination of AD patients using β-amyloid (1-42) and tau levels in CSF
Hulstaert, F., Blennow, K., Ivanoiu, A., Schoonderwaldt, H. C., Riemenschneider, M., Deyn, P. P. D., Bancher, C., Cras, P., Wiltfang, J., Mehta, P. D., et al. (1999) · Neurology · doi:10.1212/wnl.52.8.1555 · Cited by 724
Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”
(1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00022-0 · Cited by 666
Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice
Andreasen, N., Minthon, L., Davidsson, P., Vanmechelen, E., Vanderstichele, H., Winblad, B., & Blennow, K. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.373 · Cited by 573
Vandermeeren, M., Mercken, M., Vanmechelen, E., Six, J., Van de Voorde, A., Martin, J., & Cras, P. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb09823.x · Cited by 495
Vanmechelen, E., Vanderstichele, H., Davidsson, P., Van Kerschaver, E., Van Der Perre, B., Sjögren, M., Andreasen, N., & Blennow, K. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01036-3 · Cited by 488
Clinical-Neuropathological Correlations in Alzheimer's Disease and Related Dementias
Galasko, D., Hansen, L. A., Katzman, R., Wiederholt, W., Masliah, E., Terry, R., Hill, L. R., Lessin, P., & Thal, L. J. (1994) · Archives of Neurology · doi:10.1001/archneur.1994.00540210060013 · Cited by 409
MRI and CSF biomarkers in normal, MCI, and AD subjects: Predicting future clinical change
Vemuri, P., Wiste, H. J., Weigand, S. D., Shaw, L. M., Trojanowski, J. Q., Weiner, M. W., Knopman, D. S., Petersen, R. C., & Jack, C. R. (2009) · Neurology · doi:10.1212/wnl.0b013e3181af79fb · Cited by 396
Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt–Jakob disease
Otto, M., Wiltfang, J., Cepek, L., Neumann, M., Mollenhauer, B., Steinacker, P., Ciesielczyk, B., Schulz–Schaeffer, W., Kretzschmar, H. A., & Poser, S. (2002) · Neurology · doi:10.1212/wnl.58.2.192 · Cited by 289
CSF tau/Aβ 42 ratio for increased risk of mild cognitive impairment: A follow-up study
Li, G., Sokal, I., Quinn, J. F., Leverenz, J. B., Brodey, M., Schellenberg, G. D., Kaye, J. A., Raskind, M. A., Zhang, J., Peskind, E. R., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000267428.62582.aa · Cited by 279
Fluctuations of CSF amyloid-β levels: Implications for a diagnostic and therapeutic biomarker
Bateman, R. J., Wen, G., Morris, J. C., & Holtzman, D. M. (2007) · Neurology · doi:10.1212/01.wnl.0000256043.50901.e3 · Cited by 260
Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia
Engelborghs, S., De Vreese, K., Van de Casteele, T., Vanderstichele, H., Van Everbroeck, B., Cras, P., Martin, J.-J., Vanmechelen, E., & De Deyn, P. P. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.02.016 · Cited by 257
Verwey, N. A., van der Flier, W. M., Blennow, K., Clark, C., Sokolow, S., De Deyn, P. P., Galasko, D., Hampel, H., Hartmann, T., Kapaki, E., et al. (2009) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1258/acb.2009.008232 · Cited by 169
Self-citationWallin, A., Blennow, K., Andreasen, N. C., & Minthon, L. (2006) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000090631 · Cited by 168
Tau and Aβ42 protein in CSF of patients with frontotemporal degeneration
Riemenschneider, M., Wagenpfeil, S., Diehl, J., Lautenschlager, N., Theml, T., Heldmann, B., Drzezga, A., Jahn, T., Förstl, H., & Kurz, A. (2002) · Neurology · doi:10.1212/wnl.58.11.1622 · Cited by 168
Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer’s disease
Welge, V., Fiege, O., Lewczuk, P., Mollenhauer, B., Esselmann, H., Klafki, H.-W., Wolf, S., Trenkwalder, C., Otto, M., Kornhuber, J., et al. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-008-0177-6 · Cited by 152
Longitudinal changes of CSF biomarkers in memory clinic patients
Bouwman, F. H., van der Flier, W. M., Schoonenboom, N. S. M., van Elk, E. J., Kok, A., Rijmen, F., Blankenstein, M. A., & Scheltens, P. (2007) · Neurology · doi:10.1212/01.wnl.0000271375.37131.04 · Cited by 126
Self-citationKapaki, E., Paraskevas, G. P., Zalonis, I., & Zournas, C. (2003) · European Journal of Neurology · doi:10.1046/j.1468-1331.2003.00562.x · Cited by 91
Büerger, K., Frisoni, G. B., Uspenskaya, O., Ewers, M., Zetterberg, H., Geroldi, C., Binetti, G. G., Johannsen, P., Rossini, P. M., Wahlund, L., et al. (2009) · Experimental Gerontology · doi:10.1016/j.exger.2009.06.003 · Cited by 65
Diagnostic accuracy of Alzheimer’s disease: A clinicopathological study
Jellinger, K. A. (1996) · Acta Neuropathologica · doi:10.1007/s004010050418 · Cited by 64
Biomarker profiles and their relation to clinical variables in mild cognitive impairment
Schoonenboom, S. N. M., Visser, P. J., Mulder, C., Lindeboom, J., van Elk, E. J., van Kamp, G. J., & Scheltens, P. (2005) · Neurocase · doi:10.1080/13554790490896785 · Cited by 58
Self-citationKester, M. I., Blankenstein, M. A., Bouwman, F. H., van Elk, E. J., Scheltens, P., & van der Flier, W. M. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-0999 · Cited by 53
Self-citationNeurochemical approaches of cerebrospinal fluid diagnostics in neurodegenerative diseases
Otto, M., Lewczuk, P., & Wiltfang, J. (2008) · Methods · doi:10.1016/j.ymeth.2007.06.012 · Cited by 46
CSF markers related to pathogenetic mechanisms in Alzheimer's disease
Mulder, C., Schoonenboom, S. N. M., Wahlund, L., Scheltens, P., van Kamp, G. J., Veerhuis, R., Hack, C. E., Blomberg, M. E., Schutgens, R. B. H., & Eikelenboom, P. (2002) · Journal of Neural Transmission · doi:10.1007/s00702-002-0763-y · Cited by 43
Self-citationDall’Asta, C., Barbetta, L., Libé, R., Passini, E., & Ambrosi, B. (2002) · Hormone Research in Paediatrics · doi:10.1159/000058381 · Cited by 38
Variability in longitudinal cerebrospinal fluid tau and phosphorylated tau measurements
Verwey, N. A., Bouwman, F. H., van der Flier, W. M., Veerhuis, R., Scheltens, P., & Blankenstein, M. A. (2008) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2008.241 · Cited by 16
Self-citation
Cited by
Optimizing Patient Care and Research: The Amsterdam Dementia Cohort
van der Flier, W. M., Pijnenburg, Y. A. L., Prins, N., Lemstra, A. W., Bouwman, F. H., Teunissen, C. E., van Berckel, B. N. M., Stam, C. J., Barkhof, F., Visser, P. J., et al. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-132306 · Cited by 398
Self-citationAmsterdam Dementia Cohort: Performing Research to Optimize Care
van der Flier, W. M., & Scheltens, P. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170850 · Cited by 390
Self-citationSystematic Review of miRNA as Biomarkers in Alzheimer’s Disease
Swarbrick, S., Wragg, N., Ghosh, S., & Stolzing, A. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1500-y · Cited by 350
del Campo, M., Mollenhauer, B., Bertolotto, A., Engelborghs, S., Hampel, H., Simonsen, A. H., Kapaki, E., Kruse, N., Le Bastard, N., Lehmann, S., et al. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.12.46 · Cited by 343
Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes
Verberk, I. M. W., Slot, R. E., Verfaillie, S. C. J., Heijst, H., Prins, N. D., van Berckel, B. N. M., Scheltens, P., Teunissen, C. E., & van der Flier, W. M. (2018) · Annals of Neurology · doi:10.1002/ana.25334 · Cited by 315
Self-citation
Metadata
- Authors
- Mulder, C., Verwey, N. A., van der Flier, W. M., Bouwman, F. H., Kok, A., van Elk, E. J., Scheltens, P., & Blankenstein, M. A.
- Venue
- Clinical Chemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-02-01
- Volume
- 56
- Issue
- 2
- Pages
- 248-253
- ISSN
- 0009-9147 (ISSN-L)
- 1530-8561
- OpenAlex
- W2033572099
- Cited by
- 335
- References
- 35
- FWCI
- 8.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.